Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22,14:00-17:30
Next-Generation Innovative Therapies Breakthrough Session
Stay tuned
Meeting Planning
Jiandong Yuan:Chairman, BrightGene
Jin Liu:CEO, Laurel VentureCapital
14:00-14:30 The Path to Breakthroughs in Metabolic, Oncologic, and Autoimmune Diseases(Tentative)
Jiandong Yuan: Chairman, BrightGene
14:30-14:50 The Immune System, Chronic Disease, and Aging
Jianzhu Chen:Tenured Professor, Massachusetts Institute of Technology (MIT)
14:50-15:10 Next-Generation MCE Innovative Drug Products
John Li: Chairman & General Manager, Latticon
15:10-15:30 Novel Immunotherapy: The DCAR Platform — Technology Innovation, Progress, and Market Opportunities
Renhuan Xu: Co-Founder & Chief Scientific Officer, Pinion
15:30-15:50 Next-Generation Oral Biologics Delivery Platform
Liu Dou: Founder, Oralead Pharma
15:50-16:10 Break
16:10-16:30 Targeting Mitochondrial Energy Metabolism for Cancer Therapy
Yufeng Shi: Founder, Shijiang Biotech; Professor, Tongji University
16:30-16:50 AI-Driven Next-Generation Drug Discovery and Development
Jingfang Wang: Chairman & General Manager, MERNA
16:50-17:10 Exploring Next-Generation ADC Platforms Driven by Modular Design
Yu Zhang: CEO, Nalian Bio
17:10-17:30 Next-Generation AAV Gene Therapy: Reshaping the Treatment of Hereditary Hearing Loss
Yao Lu:Director of Operations and Clinical Affairs, EmayGene